# Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

> **NCT05621005** · PHASE2 · COMPLETED · sponsor: **Samar Atef Sebaweh Mohammed** · enrollment: 104 (actual)

## Conditions studied

- Ascites Infection

## Interventions

- **DRUG:** Rifaximin 550 milligram Oral Tablet [XIFAXAN]

## Key facts

- **NCT ID:** NCT05621005
- **Lead sponsor:** Samar Atef Sebaweh Mohammed
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2022-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621005, "Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05621005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*